Back to results
US 2022/0204961 A1Published application
Modified ddah polypeptides comprising a pharmacokinetic enhancing moiety, improved pharmacology and their uses
AssigneeThe Trustees of Indiana University
InventorJaipal SINGH
Life of this patent
Estimating the term…
Abstract
Modified DDAH polypeptides and their uses thereof are provided. Exemplary embodiments provide DDAH polypeptides which include one or more amino acid substitutions, additions, or deletions with natural or non-naturally encoded amino acids, and/or linkage to other biologically active molecules including other DDAH polypeptides, as well as PKEM. Additionally, use of said DDAH polypeptides for treatment of disease, such as heart failure or renal disease, is also provided.
Claims4
A modified DDAH polypeptide comprising
- a DDAH amino acid sequence having at least 95% sequence identity to SEQ ID NO:
- 1;
- SEQ ID NO:
- 2;
- SEQ ID NO:
- 5;
- SEQ ID NO:
- 6;
- SEQ ID NO:
- 7;
- SEQ ID NO:
- 9;
- SEQ ID NO:
- 10;
- SEQ ID NO:
- 11;
- SEQ ID NO:
- 12;
- SEQ ID NO:
- 13;
- or SEQ ID NO:
- 14;
- and
- a solid support, wherein said DDAH amino acid sequence is covalently linked to said solid support.
21 more elements
Dependencies are inferred from the claim text.